Humabs BioMed SA – Product Pipeline Review

Global Markets Direct’s, ‘Humabs BioMed SA – Product Pipeline Review – 2016’, provides an overview of the Humabs BioMed SA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Humabs BioMed SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Humabs BioMed SA

The report provides overview of Humabs BioMed SA including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Humabs BioMed SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Humabs BioMed SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Humabs BioMed SA’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Humabs BioMed SA

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Humabs BioMed SA’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Humabs BioMed SA Snapshot 6

Humabs BioMed SA Overview 6

Key Information 6

Key Facts 6

Humabs BioMed SA - Research and Development Overview 7

Key Therapeutic Areas 7

Humabs BioMed SA - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Humabs BioMed SA - Pipeline Products Glance 16

Humabs BioMed SA - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Humabs BioMed SA - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Humabs BioMed SA - Drug Profiles 20

Monoclonal Antibody for HCMV Infections 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

FI-6 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

mAb-100 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

mAb-114 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody for Dengue 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Monoclonal Antibody for HBV Infections 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody for Influenza B Infections 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody for Rabies 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody for Staphylococcus Aureus Infections 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

MPE-8 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NVB-71.4 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Monoclonal Antibody 1 for Undisclosed Indication 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody 2 for Undisclosed Indication 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody for Epstein-Barr Viral Infection 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody for Undisclosed Indication 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody for Viral Infections 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody for Zika Virus Infection 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Humabs BioMed SA - Pipeline Analysis 38

Humabs BioMed SA - Pipeline Products by Target 38

Humabs BioMed SA - Pipeline Products by Molecule Type 39

Humabs BioMed SA - Pipeline Products by Mechanism of Action 40

Humabs BioMed SA - Dormant Projects 41

Humabs BioMed SA - Locations And Subsidiaries 42

Head Office 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Humabs BioMed SA, Key Information 6

Humabs BioMed SA, Key Facts 6

Humabs BioMed SA – Pipeline by Indication, 2016 8

Humabs BioMed SA – Pipeline by Stage of Development, 2016 10

Humabs BioMed SA – Monotherapy Products in Pipeline, 2016 11

Humabs BioMed SA – Partnered Products in Pipeline, 2016 12

Humabs BioMed SA – Partnered Products/ Combination Treatment Modalities, 2016 13

Humabs BioMed SA – Out-Licensed Products in Pipeline, 2016 14

Humabs BioMed SA – Out-Licensed Products/ Combination Treatment Modalities, 2016 15

Humabs BioMed SA – Phase II, 2016 16

Humabs BioMed SA – Phase I, 2016 17

Humabs BioMed SA – Preclinical, 2016 18

Humabs BioMed SA – Discovery, 2016 19

Humabs BioMed SA – Pipeline by Target, 2016 38

Humabs BioMed SA – Pipeline by Molecule Type, 2016 39

Humabs BioMed SA – Pipeline Products by Mechanism of Action, 2016 40

Humabs BioMed SA – Dormant Developmental Projects,2016 41

List of Figures

List of Figures

Humabs BioMed SA – Pipeline by Top 10 Indication, 2016 8

Humabs BioMed SA – Pipeline by Stage of Development, 2016 10

Humabs BioMed SA – Monotherapy Products in Pipeline, 2016 11

Humabs BioMed SA – Pipeline by Target, 2016 38

Humabs BioMed SA – Pipeline by Molecule Type, 2016 39

Humabs BioMed SA – Pipeline Products by Mechanism of Action, 2016 40

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports